This study was sponsored by Abbott. R.L. has received honoraria for lectures or consultation from: Abbott, Asahi-Kansei, Astra-Zeneca, Celltech, Centocor, Connexion, Cosmo, Elan, InDex Pharmaceuticals, Meda, Otsuka, Pharmacia-Pfizer, Schering Plough, Schering AG, Serono, and UCB, and was partly supported by a research grant from Sophiahemmet and the Stichting af Jochnick Foundation. E.L. has received honoraria for lectures or consultation from: Abbott, AstraZeneca, Centocor, Falk, Ferring, Millenium, Schering-Plough, and UCB, and has received research grants from AstraZeneca and Schering Plough. W.R. has received honoraria for lectures or consulting from: Abbott, Aesca, Centocor, Ferring, Genetech, Novartis Pharmaceuticals, Schering-Plough, and UCB. A.M.R., M.K., A.C., and P.F.P. are employees of Abbott.
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE†
Version of Record online: 23 FEB 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 1, pages 1–9, January 2012
How to Cite
Löfberg, R., Louis, E. V., Reinisch, W., Robinson, A. M., Kron, M., Camez, A. and Pollack, P. F. (2012), Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE. Inflamm Bowel Dis, 18: 1–9. doi: 10.1002/ibd.21663
- Issue online: 11 DEC 2011
- Version of Record online: 23 FEB 2011
- Manuscript Accepted: 3 JAN 2011
- Manuscript Revised: 29 DEC 2010
- Manuscript Received: 14 OCT 2010
Additional supporting information may be found in the online version of this article.
|IBD_21663_sm_SuppFig1.tif||51K||Supporting Information Figure 1. Patient disposition|
|IBD_21663_sm_SuppTable1.doc||68K||Supporting Information Table 1.|
|IBD_21663_sm_SuppMaterials.doc||30K||Supporting Information Materials.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.